Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1303-1313

  Wang, Junling ^a   Liu, Xianchen ^b   Mullins, C Daniel ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Antidepressive agents; Depressive disorder; Diabetic neuropathies; Fibromyalgia; Low back pain; Medication adherence; Osteoarthritis

Indexed keywords

DULOXETINE; ESCITALOPRAM; VENLAFAXINE;

ADULT; ARTICLE; CHRONIC PAIN; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBROMYALGIA; HEADACHE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROLOGIC DISEASE; OSTEOARTHRITIS; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ALGORITHMS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSAGE FORMS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PAIN; RETROSPECTIVE STUDIES; SOMATOFORM DISORDERS; THIOPHENES; YOUNG ADULT;

EID: 79958797812     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.576663     Document Type: Article

References (36)

1. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53:849-57. (Pubitemid 35282613)
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75. (Pubitemid 41270106)
3. Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005;12:431-8. (Pubitemid 41445141)
4. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-9. (Pubitemid 46972905)
5. Arnold LM, Meyers AL, Sunderajan P. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008;20:187-93.
6. Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-17. (Pubitemid 44498273)
7. Duloxetine hydrochloride [prescribing information]. Indianapolis, IN: Lilly USA LLC, 2009.
8. Liu X, Ye W, Watson P, et al. Use of benzodiazepines, hypnotics, and anxiolytics in major depressive disorder: association with chronic pain diseases. J Nerv Ment Dis 2010;198:544-50.
9. National Committee on Quality Assurance. The state of health care quality. Available from http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC- 2009.pdf. [Accessed March 24, 2011].
10. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32. (Pubitemid 28558286)
11. Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcome. Am J Manag Care 2000;6:1327-36. (Pubitemid 32043656)
12. Katon W, Cantrell CR, Sokol MC, et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005;165:2497-503. (Pubitemid 41720012)
13. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41.
14. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282-90.
15. Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73.
16. Wu E, Greenberg PE, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin 2008;24:2587-95.
17. Wu EQ, Greenberg PE, Yang E, et al. Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ 2009; 12:124-35.
18. Wu E, Greenberg P, Yang E, et al. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008;24:2805-13.
19. Red Book. Thomason Reuters. 2011. Available at http://www.redbook.com/ redbook/ [Last accessed 24 March 2011].
20. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7. (Pubitemid 351160875)
21. Barron J, Wahl P, Fisher M, et al. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. P T 2008;33:532-53.
22. Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:sp11-19. (Pubitemid 46053391)
23. Duru OK, Schmittdiel JA, Dyer WT, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care 2010;16:33-40.
24. Piette JD, Heisler M, Ganoczy D, et al. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv 2007;58:207-12. (Pubitemid 46340464)
25. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther 2009;31:945-61.
26. Kornstein SG, Li D, Mao Y, et al. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 2009;14:326-33.
27. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-92. (Pubitemid 46919700)
28. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007;23:1605-14. (Pubitemid 47122170)
29. Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol 2008;23:181-7.
30. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet 2009;373:746-58.
31. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23:401-16. (Pubitemid 46333388)
32. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007;23:1303-18. (Pubitemid 46998440)
33. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22-34. (Pubitemid 47570043)
34. Schueler YB, Koesters M, Wieseler B, et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2010: published online 10 September 2010, doi: 10.1111/j.1600-0447.2010.01599.x.
35. Mullins CD, Shaya FT, Meng F, et al. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram. Clin Ther 2006;28: 297-305.
36. Mullins CD, Shaya FT, Meng F, et al. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005;25:660-7 (Pubitemid 40604881)